The genetic modification of NK cells with CAR targeting different tumor-associated antigens, including EpCAM [142,143], MUC-1 (in CRC, GC, pancreatic cancer; NCT02839954), NKG2D-L (in metastatic solid tumors; NCT03415100), and ROBO1 (in pancreatic cancer; NCT03941457), have been developed with exciting results. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.